Courtney Soubliere, DO
Endocrinology, Diabetes & Metabolism · Grand Rapids, MINPI 1275748121
Payments from drug & device makers
Across 100 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$395
- Insulet Corporation$205
- Tandem Diabetes Care, Inc.$182
- Medtronic$163
- Abbott$146
- Ascendis Pharma Endocrinology Inc$125
- plus $841 from 19 others
What the payments were for
- Food & beverage$2,04599%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $395 |
| Insulet Corporation | 6 | $205 |
| Tandem Diabetes Care, Inc. | 3 | $182 |
| Medtronic(2 entities) | 3 | $163 |
| Abbott | 2 | $146 |
| Ascendis Pharma Endocrinology Inc | 1 | $125 |
| Lilly USA, LLC | 8 | $113 |
| AstraZeneca(2 entities) | 6 | $104 |
| Xeris Pharmaceuticals, Inc. | 5 | $81 |
| Dexcom, Inc. | 4 | $75 |
| Radius Health, Inc. | 4 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Amgen(2 entities) | 3 | $61 |
| BD | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Zealand Pharma US, Inc. | 2 | $31 |
| IBSA Pharma Inc. | 2 | $23 |
| Shire North American Group Inc | 1 | $22 |
| Antares Pharma, Inc. | 1 | $21 |
| AbbVie | 1 | $20 |
| Companion Medical, Inc. | 1 | $20 |
| Alvogen Inc | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Amryt Pharma Holdings Ltd | 1 | $14 |
| Lifescan, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$128
- Yorvipath$125
- Omnipod$124
- MINIMED 780G$122
How this compares
$2,057 in reported general payments places this provider in the 50th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 250 | $316,595 |
| TrulicityDulaglutide | 178 | $206,349 |
| FarxigaDapagliflozin Propanediol | 125 | $130,346 |
| JardianceEmpagliflozin | 90 | $107,166 |
| OzempicSemaglutide | 58 | $87,784 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $59,005 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $32,939 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 167 | $32,536 |
| Humalog Kwikpen U-100Insulin Lispro | 93 | $32,501 |
| InvokanaCanagliflozin | 12 | $17,856 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 19 | $17,700 |
| HumalogInsulin Lispro | 48 | $17,502 |
| Bydureon BciseExenatide Microspheres | 13 | $17,200 |
| Levothyroxine Sodium | 716 | $12,481 |
| NovologInsulin Aspart | 38 | $11,672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev | $113 | $549,554488 claims |
| AstraZenecaFarxiga | $104 | $130,346125 claims |
| Novo NordiskOzempic, Novolog | $395 | $99,45696 claims |
| AbbVieSynthroid | $20 | $10,273106 claims |
| Sanofi-aventis U.S. LLCLantus | $37 | $2,42313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Grand Rapids
- Gregory DeinesGrand Rapids$9K
- Tobias ElseAnn Arbor$3.5M
- Elif OralAnn Arbor$2.9M
- Jamal HammoudFlint$2.6M
- Lowell SchmeltzFarmington Hills$2.3M
- George GrunbergerBloomfield Hills$1.9M
- Richard AuchusAnn Arbor$1.3M
- Ariel BarkanAnn Arbor$553K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.